Abbott Laboratories (NYSE:ABT) Stock Has Average Target Price of $119.50 According to Analysts

Shares of Abbott Laboratories (NYSE:ABT) have been given an average rating of “Moderate Buy” by the twenty-eight ratings firms that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and three have given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $119.80.

Several research firms recently commented on ABT. Citigroup boosted their price target on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a research note on Thursday, August 13th. BTIG Research boosted their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. TD Cowen restated a “buy” rating and issued a $135.00 target price on shares of Abbott Laboratories in a research note on Tuesday, September 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ABT. J. Stern & Co. LLP increased its stake in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after buying an additional 39,005,451 shares during the last quarter. Bank of America Corp DE bought a new position in Abbott Laboratories during the 2nd quarter valued at $1,603,607,000. Legal & General Group Plc acquired a new position in Abbott Laboratories during the 2nd quarter worth $1,082,524,000. Flossbach Von Storch SE bought a new stake in shares of Abbott Laboratories in the 2nd quarter worth about $902,938,000. Finally, Jupiter Topco LLC bought a new stake in shares of Abbott Laboratories in the 2nd quarter worth about $732,788,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 2.7%

Shares of Abbott Laboratories stock opened at $100.09 on Thursday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $135.24. The stock has a market cap of $173.19 billion, a price-to-earnings ratio of 32.39, a price-to-earnings-growth ratio of 1.81 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The company has a fifty day moving average price of $106.89 and a 200 day moving average price of $98.52.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period last year, the company posted $1.26 earnings per share. The firm’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.